The higher manufacturer rebate has been adopted; the investment-based exemption has not. From 1 January 2027, pharmaceutical companies will generally owe a total rebate of 15.5% on certain patent-protected medicines: the existing 7% plus an additional 8.5%. The GKV Contribution Rate Stabilisation Act, adopted on 10 July 2026, provides for this increase. The conditions under which investments in Germany or Europe could exempt a company from the additional rebate are still being developed.
Current status on 26 September 2026
The Federal Ministry of Health and the Federal Ministry for Economic Affairs and Energy convened an expert panel on 28 August 2026. It is tasked with designing a legally compliant location clause and proposing additional exemptions from the increased rebate. Its results are due on 30 September 2026. The political objective is to bring the clause into force on 1 January 2027, alongside the additional rebate.
It is therefore incorrect to claim that manufacturers producing in Germany will automatically pay a lower rebate. No final rule, definitive investment criteria or automatic entitlement based solely on a German production address has been published.
What is fixed and what remains open?
Adopted
- A total rebate of 15.5% will generally apply to the affected patent-protected medicines.
- The measure is scheduled to apply from 1 January 2027.
- The parliamentary process includes a mandate to develop additional location-related exemptions.
Still open
- Which investments qualify and at what minimum level.
- Whether eligibility will be limited to Germany or extend to the EU or EEA.
- Required duration, location commitments, evidence and clawback rules.
- Whether warehousing, packaging and distribution will count alongside R&D and production.
- How exemptions will be financed without weakening statutory health insurance savings.
Why pharmaceutical warehousing and logistics belong in the clause
Manufacturing alone does not make a medicine available. Release, packaging, serialisation, qualified storage, inventory control, transport and distribution stand between production and patient supply. A medicine may be manufactured in Germany and still be unavailable if critical logistics infrastructure fails.
- GDP-compliant capacity at 15–25 °C and 2–8 °C,
- continuous temperature monitoring, mapping and alarm management,
- redundant warehousing and distribution sites,
- validated cold chains and alternative transport lanes,
- batch traceability, serialisation and verification,
- controlled returns, quarantine and recall processes,
- safety stocks for supply-critical medicines,
- backup power, technical redundancy and business continuity plans.
This infrastructure determines whether released products reach wholesalers, hospitals and pharmacies safely and on time. A location clause intended to strengthen supply resilience should explicitly assess investment in pharmaceutical warehousing and GDP logistics.
Which logistics investments could qualify?
- Additional supply impact: demonstrably higher availability, stock reach or failure resilience for specified medicines.
- Long-term commitment: capacity and employment remain contractually available for several years.
- Regulatory quality: compliance with GDP, licensing requirements and documented qualification.
- Measurable resilience: mitigation of a defined temperature, capacity, IT or transport risk.
- Auditable evidence: investment, capacity, products, service levels and indicators can be verified.
- Clawback: relief can be corrected if commitments are not met.
Ownership should not be decisive. Qualified contract logistics and pharmaceutical 3PL can create the same resilience where capacity is contractually secured, audited and traceable to products.
A German bonus or a European supply perspective?
Pharmaceutical supply chains cross borders. A Germany-only preference may conflict with EU internal-market and state-aid rules. At the same time, proximity to the German market can shorten response times and enable alternative routes. The better question is therefore not only where a warehouse is located, but how reliably it supplies Germany and Europe.
tiger.PHARMA: from location strategy to a resilient supply chain
tiger.PHARMA connects pharmaceutical location development, GDP, QMS, warehousing and distribution. We help manufacturers and logistics partners structure investment projects, make supply benefits measurable, qualify partners and document warehouse and distribution concepts.
Consulting for pharmaceutical manufacturers · GDP warehousing and logistics · Discuss a location or supply-chain project
FAQ: location clause and manufacturer rebate
Do manufacturers producing in Germany automatically receive a lower rebate?
No. The higher rebate has been adopted, but the detailed location clause has not. A German manufacturing site alone does not currently create an automatic exemption.
When was the higher rebate adopted?
The Bundestag adopted the GKV Contribution Rate Stabilisation Act on 10 July 2026. The total rate of generally 15.5% is scheduled to apply to the affected medicines from 1 January 2027.
Can the rules still change?
The adopted additional rebate must be distinguished from the location clause still being drafted. Eligibility, scope and financing of exemptions can still change during the legislative process.
Could pharmaceutical warehousing qualify?
This has not yet been decided. There is a strong supply-security case for including GDP warehouses, cold chains, safety stocks and resilient distribution where their contribution is measurable and long-term.
Official sources
- Federal Ministry of Health, 28 August 2026
- Federal Ministry for Economic Affairs and Energy, 28 August 2026
- German Bundestag: statutory health insurance financial reform
Editorial status: 26 September 2026. The location clause has not yet been finalised. This is a professional analysis, not legal advice.